At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 8, 2026 at 07:05 ET
Regeneron Pharmaceuticals expects a $102 million acquired in-process R&D charge in Q1 2026, which will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81. This is a preliminary estimate ahead of final financial statement closing.
- Regeneron expects a $102 million acquired in-process research and development (IPR&D) charge in Q1 2026
- The charge primarily relates to premiums on equity securities purchased, development milestones, and up-front payments from collaboration and licensing agreements
- The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81
- The company notes that actual results may differ from these preliminary estimates as financial statements are not yet finalized
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access